REG - Uniphar PLC - AGM Statement

UnipharAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260507:nRSG3015Da&default-theme=true

RNS Number : 3015D  Uniphar PLC  07 May 2026

 

 

AGM Statement

 

 

Dublin, London | Thursday, 07 May 2026

 

Uniphar plc (the "Company" or "Uniphar") is holding its AGM today at 11am BST
at the office of William Fry, LLP, 6th Floor, 2 Grand Canal Square, Dublin 2,
D02 A342, Ireland.

 

At the AGM, Maurice Pratt, Chairman of Uniphar, will make the following
statement:

 

"I am pleased to report that 2025 was another great year for Uniphar, with the
business achieving its fastest rate of organic growth since IPO, with ca. 9%
organic gross profit growth. This reinforces the success of our strategy in
enhancing our ability to scale the company organically. With each of our three
divisions delivering a strong performance, the business achieved 21% adjusted
EPS growth in 2025, ahead of the Group's expectations. This was driven by a
strong trading performance, lower finance costs and accretion from the €35m
share buy-back programme completed in the period.

 

The Group continues to maintain a strong liquidity position, with Net Bank
Debt/EBITDA of 1.6x at year end. We have now delivered a significant 6-year
EPS CAGR of 16%, and we remain confident of reaching our €200m EBITDA target
by 2028, with at least 80% of our growth being organic.

 

I am happy to report that 2026 has started well, with performance in the first
four months in line with the Board's expectations. Uniphar remains well
positioned to deliver organic gross profit growth across each division in line
with previous guidance and to deliver on expectations for the full year.

 

M&A continues to play an important role in Uniphar's growth strategy, and
the Group maintains a disciplined approach to capital allocation, while
managing an active pipeline of acquisition opportunities to further enhance
the Group's growth potential.

 

Sustainability remains a key priority for the Group and shapes how the
business operates day-to-day. Based on

our recent double materiality assessment, we have a clear focus across the
Environment, Social and

Governance themes and continue to make good progress.

 

Finally, as I retire as Chairman this year, I would like to thank our
shareholders for their consistent support over the years. I'd also like to
express my pride in what the Uniphar team - management, fellow Directors and
all our global colleagues - have achieved thus far. I have every confidence
that they will continue to grow the business, constantly finding innovative
ways to enhance the services we offer to our healthcare clients and their
patients."

 

 

 

--- ENDS ---

 

 

Contact details

 Uniphar Group                                            Tel: +353 (0) 1 428 7777

 Allan Smylie, Head of Strategy and IR

 Davy (Joint Corporate Broker, Nominated Advisor and      Tel: +353 (0) 1 679 6363

 Euronext Growth Listing Sponsor)

 Daragh O'Reilly

 Niall Gilchrist

 Ivan Murphy

 RBC Capital Markets (Joint Corporate Broker)             Tel: +44 (0) 20 7653 4000

 Jamil Miah

 Daniel Saveski

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)  Tel: +44 (0) 20 7710 7600

 Matt Blawat

 Ben Maddison

 Francis North

 Q4 PR                                                    Tel: +353 (0) 1 475 1444

 Iarla Mongey, Public Relations Advisor to Uniphar Group

 

 

About Uniphar plc

Headquartered in Dublin, Ireland, Uniphar is an international diversified
healthcare services business servicing the requirements of more than 200
multinational pharmaceutical and medical technology manufacturers across three
divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain &
Retail. The Group is active in Europe, North America, APAC and MENA and
delivers to 160+ countries.

 

The Company's vision is to improve patient access to pharmaco-medical products
and treatments by enhancing connectivity between manufacturers and healthcare
stakeholders. Uniphar represents a strong combination of scale, growth, and
profitability.

 

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the
lifecycle of a pharmaceutical product. We enable pharma and biotech companies
to bring innovative medicines to global markets and provide healthcare
professionals with access to medicines they cannot source through traditional
channels. Our strategy is to build a leading platform to provide the
specialist support and expertise needed to improve access to these medicines.

 

Uniphar Medtech

Uniphar Medtech is a leading pan-European medical device distributor and
solutions partner. The Group's strategy for Uniphar Medtech is to grow our
service offering across Europe and expand our addressable market by serving
new specialities and new manufacturers.

 

 

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in
Ireland with a growing symbol group offering of retail pharmacies. The Group's
strategy for Uniphar Supply Chain & Retail is to grow our wholesale market
share, our symbol group network and our own brand, in-licenced and consumer
products portfolio.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMFLFSEERIRIIR



            Copyright 2019 Regulatory News Service, all rights reserved